Electrical Stimulation in Patients With Unipolar Major Depression

Phase 2

Completed

• Conditions: Depression
• Interventions: Procedure: Placebo stimulation of the trigeminal nerve (placebo); Procedure: Stimulation of the trigeminal nerve (active stimulation)

• Registration Number: NCT02239809
• Lead Sponsor: Hospital do Coracao

Brief Summary

Double Blinded Randomized Trial of sTNS as adjuvant treatment for Major Unipolar Depressive Disorder. The primary objective is to assess the safety and tolerability of an implantable sTNS of the V1 branch of the trigeminal nerve as an adjunctive treatment for adult patients with the diagnosis of unipolar MDD (Major Depressive Disorder).

Detailed Description

Not available

Study Timeline

• Study Start: 2014-05
• Study First Submitted: 2014-08-21
• Study First Submitted QC: 2014-09-11
• Study First Posted: 2014-09-15
• Primary Completion: 2016-05
• Study Completion: 2016-07
• Status Verified: 2016-09
• Last Update Submitted: 2016-09-28
• Last Update Posted: 2016-09-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Outpatients with non-psychotic, unipolar Major Depressive Disorder assessed via the MINI structured interview and legally capacitated to sign the informed consent for participation in the study;
• A score of ≥ 14 on the HAM-D17 with Item 1 (depressed mood) ≥ 2;
• A history of treatment failure with at least 3 adequate trials antidepressants over the previous 6 weeks and less than 6 medications, with no change in antidepressant medication or dose within the previous 6 weeks, and ongoing use of at least one antidepressant (which will continue during participation in the study);
• Patients with suicidal ideation are eligible only if the thoughts of death or of life not being worth living are not accompanied by a plan or intention for self-harm and lack of self-harming attempt in the past 6 months;
• Patients with appropriate support to be compliant with the study protocol.

Exclusion Criteria

• Patient is mentally or legally incapacitated, unable to give informed consent.
• Patients with psychosis (psychotic depression, schizophrenia, or schizoaffective diagnoses (lifetime); bipolar disorder (lifetime); dementia (lifetime); delirium or any substance abuse disorder within the past 6 months; eating disorder within the past year; obsessive-compulsive disorder (lifetime); post-traumatic stress disorder within the past year; acute risk for suicide or self-injurious behavior. Patients with diagnostic uncertainty or ambiguity (e.g. rule-out pseudo-dementia of depression) will be excluded.
• Patients currently receiving more than six medications for treatment of MDD;
• Patients with exposure to ECT or rTMS or any investigational treatment (for any disorder) within the past 6 months;
• Prior VNS and/or DBS therapy (lifetime);
• Past history of skull fracture; cranial surgery entering the calvarium; space occupying intracranial lesion; stroke, CVA, or TIAs; cerebral aneurysm; Parkinson's or Huntington's disease; or Multiple Sclerosis;
• Current pregnancy, breast feeding, plans to become pregnant during the study, or not using a medically accepted means of contraception;
• Other medical conditions that would increase the risk of infection or surgical related morbidity and/or would affect compliance with the study protocol.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo Stimulation	Placebo stimulation of the trigeminal nerve (placebo)	Patients assigned to the placebo arm did not receive stimulation electrical stimulation for 24 weeks. After this period the participants randomized to sham stimulation will be moved to the active stimulation and will be followed until study completion.
Active Stimulation	Stimulation of the trigeminal nerve (active stimulation)	Patients assigned to active stimulation arm will receive electrical stimulation during the study.

Primary Outcome Measures

Name	Time	Method
Identify a efficacy of sTNS of the V1 branch of the trigeminal nerve	12 months	We will use the Hamilton Rating Scale for Depression (HRSD) 17 scores as the main outcome measure to assess the efficacy of sTNS of the V1 branch of the trigeminal nerve as adjunctive treatment for MDD.

Secondary Outcome Measures

Name	Time	Method
Identify the tolerability of sTNS stimulation	12 months	Tolerability will be evaluated by the records of adverse effects observed during the randomized, open stimulation. We will apply the Ugvalg for Kliniske Undersgelser (UKU) scale at all visits for all patients and to compare scores between groups. Adverse events will be categorized using the MedDRA Medical Dictionary for Regulatory Activities. Complications reported by active and sham stimulation groups will be compared. The complication risk will be calculated based on the overall study duration.
Identify the long-term recurrence rate of sTNS therapy	12 months	We will calculate the recurrence rate of all participants at the end of the open label prospective follow-up. Recurrence is defined as return of HAM-17 scores equal to or superior to the original, after the patient has lodged during partial response (20% decrease of the initial score) or complete response (50% decrease of the initial score).
Identify the duration of the placebo effect	12 months	To evaluate the duration of the placebo effect in participants randomized to sham stimulation during the initial 12 weeks of the trial. The mean, median and the standard deviation of the interval time to recurrence will be calculated on placebo stimulation.

Trial Locations

Locations (1)

Hospital do Coracao; 🇧🇷 Sao Paulo, Brazil